An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Ascletis, a biotech company, has started the first-in-human safety testing in the United States of a new oral drug called ASC36. This is an early-stage clinical trial (Phase I), which mainly checks whether the medicine is safe and how the body handles it, not yet whether it works well for weight loss. ASC36 is described as an "amylin receptor peptide agonist" and that sounds complex, but it helps to break it down. A peptide is a small piece of a protein — think of it as a tiny biological messenger. "Amylin" is a naturally occurring hormone released with insulin from the pancreas; it helps regulate appetite and stomach emptying. An "agonist" means the drug mimics the hormone and activates the same receptor (the cell's switch) that amylin uses. So ASC36 is a lab-made peptide that aims to activate amylin receptors to reduce hunger or slow digestion, and it’s being developed to treat obesity. Importantly, Ascletis says this version is oral — taken by mouth — which is notable because many peptide drugs today are injected. What the announcement actually reports is only that the Phase I trial has begun in the U.S. It does not provide results yet, nor does it claim proof that ASC36 causes weight loss in people. Phase I trials typically involve a small number of healthy volunteers or sometimes people with the target condition, and they mainly measure safety, side effects, and how the drug is absorbed and cleared. So at this stage we should expect information about tolerability and dosing before any real evidence about effectiveness becomes available. No data about how well it works or how it compares to existing medications was included in the announcement. Why this could matter is straightforward: obesity is common and existing treatments don't work for everyone. If an oral amylin agonist is safe, tolerable, and later proves effective, it could offer an additional option for people trying to lose weight or manage metabolic health. An oral peptide would be especially attractive to people who prefer pills over injections. Still, this is just the first step in a long process; showing safety in Phase I is necessary but far from sufficient to prove a drug is useful. There are important caveats and risks. Early trials can reveal side effects or problems that stop development. Peptide drugs sometimes have digestive or nausea-related side effects because of how they act on appetite and stomach emptying. Regulatory approval will require larger and longer studies to show both safety and meaningful benefit. Also, the announcement doesn’t say who is in the trial, how many participants there are, or when results might be reported. Until peer-reviewed data are published, we should treat this as a development to watch rather than evidence that ASC36 will become an effective treatment. Bottom line: Ascletis has begun a first human safety study of ASC36, an oral peptide designed to mimic the appetite-regulating hormone amylin — it’s an early, cautious step toward a possible new obesity treatment, but no effectiveness data are available yet.
Source: Macau Business